Tegucigalpa, Honduras – Crassula Pharmaceuticals, a leader in cardiovascular healthcare solutions, is thrilled to announce the market introduction of Vascutan, an Irbesartan-based medication, in Honduras. This strategic expansion of Crassula’s cardiovascular portfolio underscores the company’s commitment to combating hypertension and associated cardiac conditions.

Irbesartan, the active ingredient in Vascutan, is a potent angiotensin II receptor blocker (ARB) that effectively lowers blood pressure by relaxing blood vessels. The introduction of Vascutan aims to provide patients with a reliable and efficient option for managing hypertension, which is a major risk factor for heart disease and stroke.

“Crassula Pharmaceuticals is dedicated to enhancing patient health through innovative and effective treatments. The launch of Vascutan demonstrates our commitment to addressing the urgent needs of hypertensive patients,” said Mr. Arturo Yidi, COO of Crassula. “We believe Vascutan will play a critical role in improving the cardiovascular health of the Honduran population.”

Vascutan is now available in Honduras, providing a new tool in the fight against high blood pressure and its complications. For more information about Vascutan and other Crassula products, please visit www.crassulapharma.com or contact sales@crassulapharma.com.

About Crassula Pharmaceuticals

Crassula specializes in high-quality healthcare products that focus on innovation, quality, and patient safety. Our mission is to improve health and well-being in Honduras and beyond, with a diverse product range that addresses various therapeutic areas and healthcare needs.